MPLT Phase 2 readout: a positive outcome, +6.2%

On June 4, 2026, ML-007C-MA BID — MapLight Therapeutics, Inc. (Schizophrenia) reached its Phase 2 readout. The result was a positive outcome, and the stock moved +6.2% in the window around the event. It had already run +6.6% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.